SGMT · NASDAQ · Biotechnology

Sagimet Biosciences (SGMT)

Develops selective FASN inhibitors for metabolic, dermatology, and oncology indications.

$11.18
Pre-market+0.18 (+1.64%)
At close$11.00(+4.76%)

Something off on this page? Send us feedback.

Next report
Nov 12, 2026
estimated · in 70 days
EPS estimate
−$0.25
Revenue estimate
$166.7K
Fiscal quarter
Q3 FY26

EPSReportedEstimate

May '25Aug '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
Reported−$0.56−$0.32−$0.40−$0.29−$0.33−$0.26−$0.26Pending
Estimate−$0.79−$0.52−$0.41−$0.43−$0.39−$0.25−$0.28−$0.25
Surprise+29.1%+38.5%+2.4%+32.6%+15.4%−3.6%+7.1%

RevenueReportedEstimate

May '25Aug '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
ReportedPending
Estimate$1.1M$166.7K
Surprise

History

DateEstimateReportedSurprise
Nov 2026−$0.25
Aug 2026−$0.28−$0.26+7.1%
Aug 2026−$0.25−$0.26−3.6%
May 2026−$0.39−$0.33+15.4%
Mar 2026−$0.43−$0.29+32.6%

The latest year is open to everyone — the 17 quarters behind it read with an account.

Sign in
Nov 2025
Aug 2025
May 2025
Mar 2025
Nov 2024
Aug 2024
May 2024
Mar 2024
Nov 2023
Jul 2023
Mar 2023
Dec 2022
Sep 2022
Jun 2022
Mar 2022
Mar 2021
Mar 2020
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Nov 12, 2026−$0.25$166.7K
Aug 12, 2026−$0.28−$0.26+7.1%−1.4%
Aug 11, 2026−$0.25−$0.26−3.6%−0.5%
May 12, 2026−$0.39−$0.33+15.4%−0.7%
Mar 11, 2026−$0.43−$0.29+32.6%$1.1M−7.0%

The latest year is open to everyone — the 17 quarters behind it read with an account.

Sign in
Nov 13, 2025
Aug 13, 2025
May 8, 2025
Mar 12, 2025
Nov 14, 2024
Aug 14, 2024
May 15, 2024
Mar 25, 2024
Nov 13, 2023
Jul 14, 2023
Mar 31, 2023
Dec 31, 2022
Sep 30, 2022
Jun 30, 2022
Mar 31, 2022
Mar 31, 2021
Mar 31, 2020